Overview of the drug development pipeline for anaplastic thyroid cancer
Anaplastic thyroid cancer is one of the fastest growing thyroid cancers and is known as anaplastic thyroid carcinoma or undifferentiated thyroid cancer. This condition majorly occurs in individuals living in a setup of previous thyroid pathology and iodine-inadequate areas. Patients suffering from this cancer experience symptoms such as hoarseness or changing the voice, lower neck lump, coughing up blood, loud breathing, and difficulty in swallowing. Technavio’s market research analysts have predicted that with the introduction of surgical care and medical care as some of the most promising approaches to treat anaplastic thyroid cancer, and there will be a significant increase in the global anaplastic thyroid cancer market growth in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase II development stage. For instance, sponsors such as Novartis developed Ceritinib and Eisai developed Lenvatinib, which are under the phase II stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under the pre-clinical and phase I/II development stages. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under the phase I stage.
Anaplastic thyroid cancer market worth: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of anaplastic thyroid cancer. In addition to providing information on various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Eisai
- Novartis AG
- Plexxikon
Therapeutic assessment of the drug development pipeline for anaplastic thyroid cancer by preferred route of administration
- Oral
- Intravenous
According to anaplastic thyroid cancer market insights, the oral route of administration (ROA) involves the administration of drug substances through a mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.
Therapeutic assessment of the drug development pipeline for anaplastic thyroid cancer by therapeutic modalities
- Small molecule
- Monoclonal antibody
Based on the global anaplastic thyroid cancer market dynamics, the majority of molecules that are currently in the drug development pipeline for anaplastic thyroid cancer are being developed as small molecules. Small molecules are chemically manufactured active substances that are able to enter the cells easily because of their low molecular weight.
Key questions answered in the report include
- What are the drug development molecules in the various development stages for anaplastic thyroid cancer?
- What are the companies that are currently involved in the development of drug molecules for anaplastic thyroid cancer?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.